Open Access<p>Autologous Cytokine-Induced Killer Cell Immunotherapy for Patients with High-Risk Diffuse Large B Cell Lymphoma After the First Complete Remission</p>
Author(s) -
Min Zhou,
Jing Wang,
Cuiping Li,
Jingyan Xu,
Bing Chen
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s254291
Subject(s) - medicine , cytokine induced killer cell , peripheral blood mononuclear cell , immunotherapy , cd8 , lymphoma , cd3 , diffuse large b cell lymphoma , gastroenterology , immunology , lymphocyte , oncology , immune system , biology , biochemistry , in vitro
To evaluate whether autologous cytokine-induced killer (CIK) cell immunotherapy improves the prognosis of patients with high-risk diffuse large B cell lymphoma (DLBCL) after the first complete remission (CR).